STAT Plus After a highprofile clinical failure in 2016 investor interest in the muchhyped field of microbiome science chilled. Now the industry is starting to rebound. httpsbuff.ly2Y5K1DWÂ
STAT Plus: After a high-profile clinical failure in 2016, investor interest in the much-hyped field of microbiome science chilled. Now, the industry is starting to rebound. https://buff.ly/2Y5K1DW
07:00 EDT 19 Mar 2019 |
STAT
More From BioPortfolio on "STAT Plus: After a high-profile clinical failure in 2016, investor interest in the much-hyped field of microbiome science chilled. Now, the industry is starting to rebound. https://buff.ly/2Y5K1DW "